|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun Y, Liu JH, Jin L, Sui YX, Han LL and
Huang Y: Effect of autophagy-related beclin1 on sensitivity of
cisplatin-resistant ovarian cancer cells to chemotherapeutic
agents. Asian Pac J Cancer Prev. 16:2785–2791. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu PN, Yan MD, Lai HC, Huang RL, Chou YC,
Lin WC, Yeh LT and Lin YW: Downregulation of miR-29 contributes to
cisplatin resistance of ovarian cancer cells. Int J Cancer.
134:542–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun Y, Liu JH, Jin L, Sui YX, Lai L and
Yang Y: Inhibition of Beclin 1 expression enhances
cisplatin-induced apoptosis through a mitochondrial-dependent
pathway in human ovarian cancer SKOV3/DDP cells. Oncol Res.
21:261–269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miao Y, Lu M, Yan Q, Li S and Feng Y:
Inhibition of proliferation, migration, and invasion by knockdown
of pyruvate kinase-M2 (PKM2) in ovarian cancer SKOV3 and OVCAR3
cells. Oncol Res. 24:463–475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Teng Y, Zuo X, Hou M, Zhang Y, Li C, Luo W
and Li X: A Double-negative feedback interaction between
MicroRNA-29b and DNMT3A/3B contributes to ovarian cancer
progression. Cell Physiol Biochem. 39:2341–2352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang Z, Zhang Y, Cao R, Li L, Zhong K,
Chen Q and Xiao J: miR-5195-3p inhibits proliferation and invasion
of human bladder cancer cells by directly targeting oncogene KLF5.
Oncol Res. 25:1081–1087. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X and Chen J: MiR-3188 regulates cell
proliferation, apoptosis, and migration in breast cancer by
targeting TUSC5 and regulating the p38 MAPK signaling pathway.
Oncol Res. May 26–2017.(Epub ahead of print). View Article : Google Scholar
|
|
12
|
Zhou Y, Yang C, Wang K, Liu X and Liu Q:
MicroRNA-33b inhibits the proliferation and migration of
osteosarcoma cells via targeting hypoxia-inducible factor-1α. Oncol
Res. 25:397–405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang M, Zhai X, Ge T, Yang C and Lou G:
MiR-181a-5p Promotes proliferation and invasion, and inhibits
apoptosis of cervical cancer cells via regulating inositol
polyphosphate-5-phosphatase A (INPP5A). Oncol Res. Jun
23–2017.(Epub ahead of print). View Article : Google Scholar
|
|
14
|
Wang C, Zhou B, Liu M, Liu Y and Gao R:
miR-126-5p restoration promotes cell apoptosis in cervical cancer
by targeting Bcl2l2. Oncol Res. 25:463–470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Xiang Z, Liu Y, Xu B and Tang J:
MicroRNA-133b inhibits proliferation, cellular migration, and
invasion via targeting LASP1 in hepatocarcinoma cells. Oncol Res.
25:1269–1282. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Colamaio M, Puca F, Ragozzino E, Gemei M,
Decaussin-Petrucci M, Aiello C, Bastos AU, Federico A, Chiappetta
G, Del Vecchio L, et al: miR-142-3p down-regulation contributes to
thyroid follicular tumorigenesis by targeting ASH1L and MLL1. J
Clin Endocrinol Metab. 100:E59–E69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghanbari R, Mosakhani N, Asadi J, Nouraee
N, Mowla SJ, Yazdani Y, Mohamadkhani A, Poustchi H, Knuutila S and
Malekzadeh R: Downregulation of plasma MiR-142-3p and MiR-26a-5p in
patients with colorectal carcinoma. Iran J Cancer Prev.
8:e23292015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang J, Shan WF, Jin TT, Wu GQ, Xiong XX,
Jin HY and Zhu SM: Propofol exerts anti-hepatocellular carcinoma by
microvesicle-mediated transfer of miR-142-3p from macrophage to
cancer cells. J Transl Med. 12:2792014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ramis MR, Esteban S, Miralles A, Tan DX
and Reiter RJ: Caloric restriction, resveratrol and melatonin: Role
of SIRT1 and implications for aging and related-diseases. Mech
Ageing Dev. 146–148:28–41. 2015. View Article : Google Scholar
|
|
20
|
Shuang T, Wang M, Zhou Y and Shi C:
Over-expression of Sirt1 contributes to chemoresistance and
indicates poor prognosis in serous epithelial ovarian cancer (EOC).
Med Oncol. 32:2602015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mvunta DH, Miyamoto T, Asaka R, Yamada Y,
Ando H, Higuchi S, Ida K, Kashima H and Shiozawa T: SIRT1 regulates
the chemoresistance and invasiveness of ovarian carcinoma cells.
Transl Oncol. 10:621–631. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Javadi S, Ganeshan DM, Qayyum A, Iyer RB
and Bhosale P: Ovarian cancer, the revised FIGO staging system, and
the role of imaging. AJR Am J Roentgenol. 206:1351–1360. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schwickert A, Weghake E, Brüggemann K,
Engbers A, Brinkmann BF, Kemper B, Seggewiß J, Stock C, Ebnet K,
Kiesel L, et al: microRNA miR-142-3p inhibits breast cancer cell
invasiveness by synchronous targeting of WASL, integrin alpha V,
and additional cytoskeletal elements. PLoS One. 10:e01439932015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao P and Liu WL: MiR-142-3p functions as
a potential tumor suppressor directly targeting HMGB1 in
non-small-cell lung carcinoma. Int J Clin Exp Pathol.
8:10800–10807. 2015.PubMed/NCBI
|
|
26
|
Wu X, Zhi X, Liu M, Xie J and Zhao S:
[Elevated levels of dendritic cell-correlated miRNAs in ascites and
sera of patients with ovarian cancer]. Xi Bao Yu Fen Zi Mian Yi Xue
Za Zhi. 31:383–386. 2015.PubMed/NCBI
|
|
27
|
Zhang Y, Liu Y and Xu X: Upregulation of
miR-142-3p improves drug sensitivity of acute myelogenous leukemia
through reducing P-glycoprotein and repressing autophagy by
targeting HMGB1. Transl Oncol. 10:410–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Zhou X, Qiao J and Bao A:
MiR-142-3p overexpression increases chemo-sensitivity of NSCLC by
inhibiting HMGB1-mediated autophagy. Cell Physiol Biochem.
41:1370–1382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Asaka R, Miyamoto T, Yamada Y, Ando H,
Mvunta DH, Kobara H and Shiozawa T: Sirtuin 1 promotes the growth
and cisplatin resistance of endometrial carcinoma cells: A novel
therapeutic target. Lab Invest. 95:1363–1373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li D, Wu QJ, Bi FF, Chen SL, Zhou YM, Zhao
Y and Yang Q: Effect of the BRCA1-SIRT1-EGFR axis on cisplatin
sensitivity in ovarian cancer. Am J Transl Res. 8:1601–1608.
2016.PubMed/NCBI
|
